Kiniksa Pharmaceuticals Interna (KNSA) Stock Price & How to Invest
Last updated November 2026
Short answer
KNSA is Kiniksa Pharmaceuticals, a profitable commercial-stage biopharma whose growth rides almost entirely on one drug, ARCALYST, in recurrent pericarditis. It is a rare profitable small-cap biotech, but the single-product concentration is the whole story. As of November 20, 2026 the stock closed near $94.14, up about 124% year to date after a third straight raise to 2026 sales guidance, which now puts ARCALYST above $1 billion for the year.
KNSA stock price
As of 2026-11-20, Kiniksa Pharmaceuticals Interna (KNSA) last closed at $93.89, up 125.8% over the past year. Over the past 52 weeks it has traded between $37.92 and $98.76.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Kiniksa Pharmaceuticals Interna's investor relations page. Walnut is informational, not investment advice.
KNSA key stats
At $93.90 on November 20, 2026, Kiniksa Pharmaceuticals Interna (KNSA) has a market cap of $7.4B and a P/E of 71.1 on trailing earnings (45.9 on forward earnings).
- Market cap
- $7.4B
- P/E (trailing)
- 71.1
- P/E (forward)
- 45.9
- EPS (trailing 12 months)
- $1.32
- Price to book
- 10.4
- Beta
- 0.08
Market cap, P/E and yield are measured at the $93.90 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.
What's new with Kiniksa Pharmaceuticals Interna (KNSA)?
The last two weeks for Kiniksa Pharmaceuticals Interna, as of November 22, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.
- KNSA closed at $93.89 on November 20, 2026, down 2.5% over the past five trading days (from $96.33).
- On November 17, 2026, TD Cowen raised its target to $115.00 from $100.00 (Buy).
Kiniksa Pharmaceuticals Interna filed no current, quarterly or annual report with the SEC in the last two weeks.
Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.
Kiniksa Pharmaceuticals Interna (KNSA) latest quarter
Kiniksa Pharmaceuticals reported revenue of $286 million for Q3 2026, up 58% from a year earlier (Kiniksa Pharmaceuticals, Oct 27, 2026).
Source: Kiniksa Pharmaceuticals Q3 2026 results, Oct 27, 2026. Full earnings breakdown
What does Kiniksa Pharmaceuticals Interna (KNSA) do?
Kiniksa Pharmaceuticals (Nasdaq: KNSA) is a commercial-stage biopharmaceutical company focused on immune-modulating and cardiovascular therapies. Its franchise is ARCALYST (rilonacept), an IL-1 blocker approved for recurrent pericarditis (a painful inflammatory condition of the heart lining) that it commercializes in the US under a collaboration with Regeneron. ARCALYST drove roughly $677.5 million of net product revenue in 2025, up about 62% from 2024. Growth kept accelerating in 2026: revenue was roughly $214.3 million in Q1 (up about 56% year over year), $243.6 million in Q2 (up about 55%) and about $286 million in Q3 (up about 58%), and management has raised full-year 2026 net product revenue guidance three times, most recently to $1.045 to $1.050 billion. About 5,450 clinicians had prescribed ARCALYST by the end of Q3, roughly 450 more than a quarter earlier, and management estimates it has reached about 23% of the roughly 14,000-patient multiple-recurrence population.
The investment picture is unusual for a biotech of this size: Kiniksa is already profitable, reporting net income of about $47.3 million in Q3 2026 and about $110 million over the trailing twelve months, with about $569 million of cash and investments and no meaningful debt. Q3 EPS of $0.56 was well above the $0.31 consensus, and the stock jumped after the October 27 report. The bull framing is expanding prescriber adoption and a shift toward chronic disease management in recurrent pericarditis, plus an internal IL-1R pipeline meant to extend the franchise beyond ARCALYST; KPL-387 is in the PASTORALE Phase 3 study at a 300 mg monthly dose, with Phase 3 data expected in the second half of 2027 and a targeted 2028-2029 launch. The bear framing is concentration risk: nearly all revenue comes from one product in one indication, and the eventual loss of exclusivity plus competitive or pipeline setbacks would hit hard given the elevated valuation (about 71 times trailing earnings and a market cap near $7.4 billion as of November 2026). Insiders sold several blocks of shares in early November 2026, including one sale worth about $14.3 million.
What's driving Kiniksa Pharmaceuticals Interna (KNSA)?
1. ARCALYST adoption in recurrent pericarditis
ARCALYST is the sole meaningful revenue driver, and growth has come from more prescribers, better patient identification, and a shift toward chronic, not one-off, treatment. About 450 clinicians wrote their first prescription in each of Q2 and Q3 2026, bringing the total to about 5,450, and Q3 revenue of about $286 million rose about 58% year over year. Full-year 2026 guidance has been raised from $930 to $945 million to $980 to $995 million and then to $1.045 to $1.050 billion. Continued penetration of the recurrent pericarditis population, still only about 23% of the multiple-recurrence pool by management's estimate, is the core near-term thrust.
2. Profitable growth profile
Unlike most small-cap biotechs, Kiniksa is already generating positive net income (about $47.3 million in Q3 2026, roughly $110 million trailing) while compounding revenue, and trailing free cash flow was about $136 million. ARCALYST collaboration profit rose about 67% to about $211.6 million in Q3, and the company added about $43 million of net cash in the quarter. That combination of growth plus profitability, alongside cash and investments of roughly $569 million and no meaningful debt, gives it room to fund its own Phase 3 program without immediate dilution, which is rare at this stage.
3. Internal IL-1R pipeline (KPL-387, KPL-1161)
KPL-387, an IL-1R1 antibody, delivered Phase 2 data in 2026 that supported a 300 mg monthly subcutaneous dose, with a median four days to treatment and pain response. It is now in PASTORALE, an event-driven randomized-withdrawal Phase 3 trial of up to about 85 participants, with Phase 3 data expected in the second half of 2027 and a targeted commercial launch in 2028-2029. KPL-1161, an Fc-modified antibody aimed at quarterly dosing, remains on track to start Phase 1 by year-end 2026. These programs aim to extend the recurrent pericarditis franchise and reduce reliance on ARCALYST over time.
4. Franchise-defense economics
By owning next-generation IL-1R assets with more convenient dosing, Kiniksa is attempting to migrate patients to internally developed products ahead of ARCALYST's eventual loss of exclusivity. Because ARCALYST profits are shared with Regeneron while KPL-387 is wholly owned, a successful switch could improve Kiniksa's economics even if headline ARCALYST sales eventually fall; failure would leave revenue exposed to competition and patent expiry.
What are the risks to Kiniksa Pharmaceuticals Interna (KNSA)?
The dominant risk is single-product concentration: essentially all revenue depends on ARCALYST in one indication, so any competitive entry, reimbursement pressure, safety signal, or eventual loss of exclusivity would be material. The stock trades at about 71 times trailing and 46 times forward earnings after more than doubling over the past year, so a growth deceleration or a guidance miss could compress the valuation sharply; quarterly EPS missed estimates in late 2025 even as revenue grew. Insiders sold several blocks of shares in November 2026 after the rally. The pipeline remains binary: a PASTORALE failure, with data expected in the second half of 2027, would remove the main franchise-extension thesis, and KPL-1161 has not yet entered the clinic. ARCALYST is co-developed with Regeneron, so collaboration economics and terms matter to Kiniksa's share of profits. As a small-cap biotech, the shares are volatile and sensitive to single data readouts.
What is the Kiniksa Pharmaceuticals Interna (KNSA) forecast?
7 analysts publish price targets on KNSA, averaging $111.57 as of November 2026, or +18.8% against the $93.90 share price on November 20, 2026. The published targets run from $98.00 to $134.00, a moderate spread, and the ratings split 7 buy, 0 hold, 0 sell. Over the last six months there have been 12 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.
Read the full KNSA forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.
Is KNSA a buy or a sell?
We give no verdict on Kiniksa Pharmaceuticals Interna. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.
The case for buying. ARCALYST adoption in recurrent pericarditis. ARCALYST is the sole meaningful revenue driver, and growth has come from more prescribers, better patient identification, and a shift toward chronic, not one-off, treatment. The most optimistic published target, $134.00, assumes this works close to its best case.
The case against. The dominant risk is single-product concentration: essentially all revenue depends on ARCALYST in one indication, so any competitive entry, reimbursement pressure, safety signal, or eventual loss of exclusivity would be material. The most pessimistic target, $98.00, is roughly what KNSA is worth if this bites instead.
Read the full bull and bear case on KNSA, including what would have to change to break either one. Walnut is not an investment adviser.
Has Kiniksa Pharmaceuticals Interna (KNSA) split its stock?
No. Kiniksa Pharmaceuticals Interna (KNSA) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.
How is Kiniksa Pharmaceuticals Interna (KNSA) valued?
Market cap, P/E and dividend yield at today's price are in the KNSA key stats above. The business figures below come from Kiniksa Pharmaceuticals Interna's reported results as of November 2026 and change when it next reports.
- Revenue (TTM): ~$946M
- Q3 2026 revenue: ~$286M (up ~58% YoY)
- Net income (TTM): ~$110M (EPS ~$1.32)
- Margins (TTM): ~54% gross, ~14% operating, ~12% net
- Cash and investments: ~$569M, no meaningful debt
- 2026 net product revenue guidance: ~$1.045-1.050B (raised from $980-995M)
As of November 2026: As of November 2026, Kiniksa carried a market cap of roughly $7.4 billion against trailing revenue near $946 million and net income around $110 million, for a trailing P/E near 71. That multiple reflects both rare biotech profitability and expectations that ARCALYST keeps compounding past the raised 2026 guidance and that analysts' forecast of about $1.35 billion of 2027 revenue and $2.05 of EPS holds. The seven analysts in Yahoo's count rate it a strong buy with a mean target near $112, and the stock is up about 124% in 2026.
Who competes with Kiniksa Pharmaceuticals Interna (KNSA)?
Recurrent pericarditis and IL-1 pathway therapies
ARCALYST (rilonacept) competes against other anti-inflammatory and IL-1 targeting approaches used off-label or in development for pericarditis, including colchicine, corticosteroids, and IL-1 blockers such as anakinra (Kineret) and canakinumab (Ilaris) from Novartis. Kiniksa's own KPL-387 and KPL-1161 are designed to eventually succeed ARCALYST within this same pathway.
Rare-disease and autoinflammatory biopharma
As a profitable specialty biopharma, Kiniksa sits alongside other rare-disease and immunology-focused names (for example companies commercializing niche IL-1, IL-6, or complement therapies) that compete for specialist prescriber attention, payer coverage, and biotech investor capital.
Collaboration partner and larger pharma
ARCALYST is commercialized under a collaboration with Regeneron, which both enables and shares the economics of the franchise. Larger immunology-focused pharma companies (such as Novartis and Sobi in the IL-1 space) have the scale to compete on future pericarditis or autoinflammatory indications.
What stocks are similar to Kiniksa Pharmaceuticals Interna (KNSA)?
Other names that sit close to KNSA: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.
How to invest in Kiniksa Pharmaceuticals Interna (KNSA)
There are three common ways to get KNSA exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so KNSA sits alongside other stocks that express the same thesis.
Walnut takes the portfolio route. Describe a thesis where KNSA fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.
The bottom line on Kiniksa Pharmaceuticals Interna (KNSA)
Kiniksa is a rare profitable biotech compounding ARCALYST sales (Q3 2026 revenue up about 58%, 2026 guidance now $1.045 to $1.050 billion), with the KPL-387 Phase 3 program and the patent cliff around ARCALYST as the two swing factors, and a share price that has more than doubled in a year.
More on Kiniksa Pharmaceuticals Interna (KNSA)
Whether KNSA is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is KNSA a buy or a sell?, and where the stock could go from here in the KNSA stock forecast.
For income investors, whether KNSA pays a dividend and how the payout looks is covered in does KNSA pay a dividend? And to weigh KNSA against a peer, read the full side-by-side comparisons: KNSA vs NVS and KNSA vs REGN.
Wondering how KNSA fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Kiniksa Pharmaceuticals Interna
Ask Walnut's AI anything about KNSA and see how it fits what you own.
FAQ
What does Kiniksa Pharmaceuticals do?
+
Kiniksa is a commercial-stage biopharmaceutical company. Its main product is ARCALYST (rilonacept), an IL-1 blocker approved for recurrent pericarditis, an inflammatory condition affecting the lining around the heart. It also develops next-generation IL-1R antibodies, led by KPL-387, now in Phase 3.
Is KNSA profitable?
+
Yes. Kiniksa reported net income of about $47.3 million in Q3 2026 and trailing net income near $110 million, which is unusual for a biotech that is still growing revenue more than 50% a year.
How fast is ARCALYST growing?
+
ARCALYST net product revenue was roughly $677.5 million in 2025, up about 62% from 2024. Revenue rose about 56% year over year in Q1 2026, about 55% in Q2 and about 58% in Q3, to about $286 million, and Kiniksa has raised 2026 guidance to $1.045 to $1.050 billion, which would take ARCALYST past $1 billion for the year.
What is the biggest risk with KNSA?
+
Concentration. Nearly all revenue comes from one product, ARCALYST, in one indication. Competition, reimbursement pressure, a safety issue, or the eventual loss of exclusivity could each have an outsized effect on the business.
What is in Kiniksa's pipeline?
+
The two internal programs are KPL-387, an IL-1R1 antibody now in the PASTORALE Phase 3 trial at a 300 mg monthly subcutaneous dose (Phase 3 data expected in the second half of 2027, targeting a 2028-2029 launch), and KPL-1161, targeting quarterly dosing (Phase 1 planned by year-end 2026). Both aim to extend the recurrent pericarditis franchise.
Why does KNSA trade at such a high P/E?
+
As of November 2026 the trailing P/E was about 71 and the forward P/E about 46. The market is pricing in continued rapid revenue growth past the raised 2026 guidance, plus the rarity of a profitable, growing biotech. That multiple leaves little room for a growth miss.
Does Kiniksa own ARCALYST outright?
+
ARCALYST is commercialized in the US under a collaboration with Regeneron, so the economics are shared. That partnership enables the franchise but means Kiniksa does not keep 100% of the product's profits.
Who competes with ARCALYST?
+
In and around recurrent pericarditis, ARCALYST faces standard-of-care options like colchicine and corticosteroids and other IL-1 pathway drugs such as anakinra (Kineret) and canakinumab (Ilaris) from Novartis. Kiniksa's own pipeline is also designed to eventually replace ARCALYST.
How did Kiniksa do in its latest quarter?
+
In Q3 2026, reported October 27, Kiniksa posted revenue of about $286 million, up about 58% year over year and above the roughly $260 million consensus, with EPS of $0.56 against a $0.31 estimate and net income of about $47.3 million. It raised 2026 guidance for the third time, to $1.045 to $1.050 billion, and ended the quarter with about $569 million of cash.
How has KNSA stock performed in 2026?
+
As of November 20, 2026, KNSA closed at $94.14, up about 124% year to date and about 127% over one year, and up about 23% over the prior month after the Q3 report. Its 52-week range was roughly $37 to $99.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Kiniksa Pharmaceuticals Interna's investor relations page or your broker before making investment decisions.